NO314066B1 - Anvendelse av en forbindelse med progesteronantagonistisk (PA) virkning ogminst ±n forbindelse med antiöstrogen (AÖ)-virkning forfremstilling av et middel beregnet for kombinert anvendelse for antikonsepsjon hos kvinner - Google Patents
Anvendelse av en forbindelse med progesteronantagonistisk (PA) virkning ogminst ±n forbindelse med antiöstrogen (AÖ)-virkning forfremstilling av et middel beregnet for kombinert anvendelse for antikonsepsjon hos kvinner Download PDFInfo
- Publication number
- NO314066B1 NO314066B1 NO19972877A NO972877A NO314066B1 NO 314066 B1 NO314066 B1 NO 314066B1 NO 19972877 A NO19972877 A NO 19972877A NO 972877 A NO972877 A NO 972877A NO 314066 B1 NO314066 B1 NO 314066B1
- Authority
- NO
- Norway
- Prior art keywords
- hydroxy
- phenyl
- dien
- estra
- antiestrogen
- Prior art date
Links
- 239000000328 estrogen antagonist Substances 0.000 title claims description 44
- 150000001875 compounds Chemical class 0.000 title claims description 35
- 230000001833 anti-estrogenic effect Effects 0.000 title claims description 29
- 229940046836 anti-estrogen Drugs 0.000 title claims description 25
- 230000009471 action Effects 0.000 title claims description 13
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title description 25
- 239000000186 progesterone Substances 0.000 title description 12
- 229960003387 progesterone Drugs 0.000 title description 12
- 230000003042 antagnostic effect Effects 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 6
- 239000003795 chemical substances by application Substances 0.000 title description 5
- 239000000044 progesterone antagonist Substances 0.000 claims description 40
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 25
- 230000002860 competitive effect Effects 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 230000035558 fertility Effects 0.000 claims description 11
- 230000027758 ovulation cycle Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- -1 3-hydroxy-17a-(3-hydroxy-1-propenyl)-estra-4,9-diene Chemical compound 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- JFEPJTGMGDGPHJ-PNKHAZJDSA-N (8r,9s,10r,13s,14s)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 JFEPJTGMGDGPHJ-PNKHAZJDSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
- 230000000624 ovulatory effect Effects 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 150000002009 diols Chemical class 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
- 229960004622 raloxifene Drugs 0.000 claims description 2
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 description 28
- 238000002513 implantation Methods 0.000 description 22
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 18
- 239000000262 estrogen Substances 0.000 description 17
- 229940011871 estrogen Drugs 0.000 description 16
- 230000016087 ovulation Effects 0.000 description 16
- 210000004696 endometrium Anatomy 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 241000700198 Cavia Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 229960001603 tamoxifen Drugs 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 10
- 239000003886 aromatase inhibitor Substances 0.000 description 9
- 229940046844 aromatase inhibitors Drugs 0.000 description 9
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 7
- 229950011093 onapristone Drugs 0.000 description 7
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 description 6
- 230000002254 contraceptive effect Effects 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 239000003418 antiprogestin Substances 0.000 description 5
- 239000003433 contraceptive agent Substances 0.000 description 5
- 102000009151 Luteinizing Hormone Human genes 0.000 description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 4
- 229960003327 ormeloxifene Drugs 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000583 progesterone congener Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002513 anti-ovulatory effect Effects 0.000 description 2
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 231100000546 inhibition of ovulation Toxicity 0.000 description 2
- 230000000938 luteal effect Effects 0.000 description 2
- 230000029849 luteinization Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229940077150 progesterone and estrogen Drugs 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000006213 vaginal ring Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JQKMNNYZQUQIJJ-UHFFFAOYSA-N 1,1-diphenylbut-1-en-2-ylbenzene Chemical compound C=1C=CC=CC=1C(CC)=C(C=1C=CC=CC=1)C1=CC=CC=C1 JQKMNNYZQUQIJJ-UHFFFAOYSA-N 0.000 description 1
- RLJHZHFTUDAXCF-UHFFFAOYSA-N 5-[cyclopentylidene(imidazol-1-yl)methyl]thiophene-2-carbonitrile Chemical group S1C(C#N)=CC=C1C(N1C=NC=C1)=C1CCCC1 RLJHZHFTUDAXCF-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241001262617 Japonica Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- QIANMKANRARWRV-UHFFFAOYSA-N acetic acid;3-[1-(3-hydroxyphenyl)-2-phenylbut-1-enyl]phenol Chemical compound CC(O)=O.CC(O)=O.C=1C=CC=CC=1C(CC)=C(C=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 QIANMKANRARWRV-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- XDFORSMZCYHNBG-UHFFFAOYSA-N benzonitrile;hydrochloride Chemical compound Cl.N#CC1=CC=CC=C1 XDFORSMZCYHNBG-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000020 developmental retardation Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229950002366 nafoxidine Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002661 non steroidal estrogen Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 239000000029 vaginal gel Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4447402 | 1994-12-23 | ||
PCT/EP1995/005106 WO1996019997A1 (de) | 1994-12-23 | 1995-12-23 | Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption |
Publications (3)
Publication Number | Publication Date |
---|---|
NO972877D0 NO972877D0 (no) | 1997-06-20 |
NO972877L NO972877L (no) | 1997-08-22 |
NO314066B1 true NO314066B1 (no) | 2003-01-27 |
Family
ID=6537602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19972877A NO314066B1 (no) | 1994-12-23 | 1997-06-20 | Anvendelse av en forbindelse med progesteronantagonistisk (PA) virkning ogminst ±n forbindelse med antiöstrogen (AÖ)-virkning forfremstilling av et middel beregnet for kombinert anvendelse for antikonsepsjon hos kvinner |
Country Status (24)
Country | Link |
---|---|
US (1) | US6362237B1 (lv) |
EP (1) | EP0799042A1 (lv) |
JP (1) | JPH10511378A (lv) |
KR (1) | KR100385663B1 (lv) |
CN (1) | CN1075375C (lv) |
AU (1) | AU710819B2 (lv) |
BG (1) | BG62384B1 (lv) |
BR (1) | BR9510550A (lv) |
CA (1) | CA2208321A1 (lv) |
CZ (1) | CZ288062B6 (lv) |
EE (1) | EE03421B1 (lv) |
FI (1) | FI972623A0 (lv) |
HU (1) | HUT77519A (lv) |
IL (1) | IL116505A0 (lv) |
LT (1) | LT4291B (lv) |
LV (1) | LV11883B (lv) |
NO (1) | NO314066B1 (lv) |
NZ (1) | NZ298769A (lv) |
PL (1) | PL183843B1 (lv) |
RO (1) | RO121086B1 (lv) |
SI (1) | SI9520136A (lv) |
SK (1) | SK284538B6 (lv) |
WO (1) | WO1996019997A1 (lv) |
ZA (1) | ZA9510926B (lv) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19652408C2 (de) * | 1996-12-06 | 2002-04-18 | Schering Ag | Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln |
DE19745085A1 (de) * | 1997-10-11 | 1999-04-15 | Jenapharm Gmbh | 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
ID24568A (id) * | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
DE19809845A1 (de) | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
US6444668B1 (en) | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
US6358947B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6380178B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
US6399593B1 (en) | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6319912B1 (en) | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
JP4382735B2 (ja) | 2005-10-06 | 2009-12-16 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
EA201070715A1 (ru) * | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2824733C2 (de) | 1978-06-06 | 1984-03-15 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Umführtrommel für Schön- und Widerdruckmaschinen |
ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
IL68222A (en) * | 1983-03-24 | 1987-02-27 | Yeda Res & Dev | Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity |
ES8502612A1 (es) | 1983-06-15 | 1985-02-01 | Schering Ag | Procedimiento para la preparacion de 13a-alquilgonanos |
DE3322285A1 (de) | 1983-06-18 | 1984-12-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3337450A1 (de) | 1983-10-12 | 1985-04-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prostaglandine und antigestagene fuer den schwangerschaftsabbruch |
NZ214998A (en) | 1985-02-07 | 1989-06-28 | Schering Ag | 13-(methyl or ethyl)-11-beta-phenyl-gonane derivatives; preparatory processes and pharmaceutical compositions |
DE3533175A1 (de) | 1985-09-13 | 1987-03-19 | Schering Ag | Antigestagene zur verschiebung der endometrialen reifung |
IE60780B1 (en) | 1987-01-23 | 1994-08-10 | Akzo Nv | New 11-aryl steroid derivatives |
DE3708942A1 (de) | 1987-03-18 | 1988-09-29 | Schering Ag | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
EP0289073B1 (en) | 1987-04-24 | 1991-11-27 | Akzo N.V. | Novel 11-aryloestrane and 11-arylpregnane derivatives |
EP0310542B1 (de) * | 1987-10-01 | 1994-06-08 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren |
DE3733478A1 (de) * | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
ATE85342T1 (de) | 1987-12-12 | 1993-02-15 | Akzo Nv | 11-arylsteroid-derivate. |
GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
DE3921059A1 (de) * | 1989-06-23 | 1991-01-10 | Schering Ag | 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
DE3926365A1 (de) | 1989-08-04 | 1991-02-07 | Schering Ag | Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln |
CH683151A5 (de) | 1991-04-24 | 1994-01-31 | Ciba Geigy Ag | Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus. |
EP0637296A4 (en) | 1992-04-21 | 1996-02-07 | Ligand Pharm Inc | NON-STEROIDIAN COMPOUNDS HAVING AGONIST AND ANTAGONIST ACTIVITY IN RELATION TO THE PROGESTERONE RECEPTOR, AND METHODS OF USE. |
US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
-
1995
- 1995-12-21 ZA ZA9510926A patent/ZA9510926B/xx unknown
- 1995-12-22 IL IL11650595A patent/IL116505A0/xx not_active IP Right Cessation
- 1995-12-23 HU HU9702074A patent/HUT77519A/hu unknown
- 1995-12-23 RO RO97-01061A patent/RO121086B1/ro unknown
- 1995-12-23 CA CA002208321A patent/CA2208321A1/en not_active Abandoned
- 1995-12-23 SI SI9520136A patent/SI9520136A/sl not_active IP Right Cessation
- 1995-12-23 KR KR1019970704319A patent/KR100385663B1/ko not_active IP Right Cessation
- 1995-12-23 CN CN95197051A patent/CN1075375C/zh not_active Expired - Fee Related
- 1995-12-23 JP JP8520204A patent/JPH10511378A/ja not_active Ceased
- 1995-12-23 PL PL95320786A patent/PL183843B1/pl not_active IP Right Cessation
- 1995-12-23 EE EE9700143A patent/EE03421B1/xx not_active IP Right Cessation
- 1995-12-23 EP EP95943194A patent/EP0799042A1/de not_active Withdrawn
- 1995-12-23 NZ NZ298769A patent/NZ298769A/xx unknown
- 1995-12-23 BR BR9510550A patent/BR9510550A/pt not_active IP Right Cessation
- 1995-12-23 SK SK789-97A patent/SK284538B6/sk unknown
- 1995-12-23 WO PCT/EP1995/005106 patent/WO1996019997A1/de active IP Right Grant
- 1995-12-23 AU AU44337/96A patent/AU710819B2/en not_active Ceased
- 1995-12-23 CZ CZ19971953A patent/CZ288062B6/cs not_active IP Right Cessation
- 1995-12-26 US US08/578,222 patent/US6362237B1/en not_active Expired - Fee Related
-
1997
- 1997-06-03 BG BG101553A patent/BG62384B1/bg unknown
- 1997-06-18 FI FI972623A patent/FI972623A0/fi unknown
- 1997-06-20 LT LT97-107A patent/LT4291B/lt not_active IP Right Cessation
- 1997-06-20 NO NO19972877A patent/NO314066B1/no unknown
- 1997-06-20 LV LVP-97-124A patent/LV11883B/lv unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO314066B1 (no) | Anvendelse av en forbindelse med progesteronantagonistisk (PA) virkning ogminst ±n forbindelse med antiöstrogen (AÖ)-virkning forfremstilling av et middel beregnet for kombinert anvendelse for antikonsepsjon hos kvinner | |
KR100348116B1 (ko) | 폐경기 및 폐경후 여성을 위한 호르몬 대체 요법에사용하기위한프로게스테론길항제및부분적아고니스트작용을갖는항에스트로겐제의조합 | |
US6143754A (en) | Competitive progesterone antagonist for demand-oriented female birth control | |
CZ2002707A3 (cs) | Pouľití mesoprogestinů (modulátorů receptoru pro progesteron) jako sloľky pro výrobu ľenských kontraceptiv | |
EP1605924B1 (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
NO324613B1 (no) | Anvendelse av en sekvenskombinasjon av ostrogen/progesteronantagonister for fremstilling av et legemiddel for hormonerstatningsterapi | |
MXPA97004742A (es) | Compuestos con propiedades antagonistas de progesterona y anti-estrogeno para su uso combinado en la anticoncepcion femenina |